Twenty patients at Penn Medicine have been cured of the hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease, according to a study published today in Annals of Internal Medicine. The researchers also report that the kidney transplants for these 20 patients are functioning just as well as kidneys that are transplanted from similar donors without HCV.
Twenty patients who received kidneys transplanted from hepatitis C virus (HCV)-infected donors experienced HCV cure, good quality of life, and excellent renal function at one year. These findings offer additional evidence that kidneys from HCV-infected donors may be a valuable transplant resource. Results from the single-group trial are published in Annals of Internal Medicine.
Refined mentorship programs, further education and understanding are cited as necessary to improve work-life balance
Researchers at Wake Forest Baptist Medical Center have shown that gene expression analysis of blood samples taken from the recipients of transplanted kidneys can be used to better understand the mechanisms that promote repair and regeneration of the transplanted organs.
Researchers have helped solve a decades-old mystery about which mutations are responsible for an inherited bone marrow disorder. The answer may allow some children to avoid the risk and expense of bone marrow transplantation, a common treatment for leukemia and bone marrow disorders. Investigators at St. Jude Children's Research Hospital and UCSF, led the study, which appears today in the scientific journal JCI Insight.The disorder is myelodysplasia and leukemia syndrome with monosomy 7.
Patients who had donor blood or marrow transplants during childhood continue to be at increased risk of premature death even years after the procedure compared with the general population, although the rate of later death among these transplant patients has decreased over the last three decades.
The lifespan of a transplant kidney has significantly improved over the last thirty years. Between 1986 and 1995, 75 percent of the transplanted kidneys still functioned five years after the transplant. Between 2006 and 2015, this number had already risen to 84 percent. However, an international study lead by kidney specialist Maarten Naesens of KU Leuven shows that the progress is stagnating.
Scientists have discovered that some treatments for cancer and sickle cell disease can destroy the germ cells that go on to develop into sperm in the testes of young boys. In some pre-pubescent boys, the treatment for sickle cell disease results in complete destruction of all their germ cells, which are called spermatogonia. The study is published in Human Reproduction and is the first to describe the effects of these treatments on spermatogonial quantity
Scientists from the New York Stem Cell Foundation (NYSCF) Research Institute have developed a new bone engineering technique called Segmental Additive Tissue Engineering (SATE). The technique, described in a paper published online today in Scientific Reports, allows researchers to combine segments of bone engineered from stem cells to create large scale, personalized grafts that will enhance treatment for those suffering from bone disease or injury through regenerative medicine.
Currently, people receiving organ transplants must take drugs to suppress the inflammatory immune response that leads to rejection. Even so, almost all recipients eventually lose their transplant. A new approach, which maintains a population of immune cells that naturally temper immune responses, known as Tregs, could greatly enhance people's long-term tolerance for transplants.